^99mTc（V）—DMSA及^99mTc—MIBI肺显像诊断原发性肺癌的应用研究

对３０例原发性肺癌患者分别应用＾９９ｍＴｃ（ｖ）－ＤＭＳＡ及＾９９ｍＴｃ－ＭＩＢＩ显像。结果表明：＾９９ｍＴｃ９Ｖ）－ＤＭＳＡ，＾９９ｍＴｃ－ＭＩＢＩ敏感度分别为９０％，７６．７％。两者结合显像阳性率为９６．７％。鳞状上皮细胞癌对＾９９ｍＴｃ（Ｖ）－ＤＭＳＡ及＾９９ｍＴｃ（Ｖ）－ＤＭＳＡ，＾９９ｍＴｃ－ＭＩＢＩ摄取程度比其它类型的肺癌高。     

99mTc-MIBI显像对甲状腺癌及术后随访的临床价值

４６例甲状腺原发肿块（恶性病变１８例,良性病变２８例）及２４例甲状腺癌术后复发或转移患者,应用＾９９ｍＴｃ－ＭＩＢＩ显像。结果１８例甲状腺癌中１４例原发灶有效射性填充。而２８例良性病变中仅９例原发灶有放射性填充。２４例甲状腺癌术后复发或转移患者有１９例呈阳性显示,其阳性率明显高于＾１３１Ｉ显像。＾９９ｍＴｃ－ＭＩＢＩ显像对甲状腺癌尤其是术后复发、转移的早期诊断具有较高的临床价值。     

~(99m)Tc(Ⅴ)-DMSA 及 ~(99m)Tc-MIBI 肺显像诊断原发性肺癌的应用研究

对３０例原发性肺癌患者分别应用９９ｍＴｃ（Ⅴ）－ＤＭＳＡ及９９ｍＴｃ－ＭＩＢＩ显像。结果表明：９９ｍＴｃ（Ⅴ）－ＤＭＳＡ、９９ｍＴｃ－ＭＩＢＩ敏感度分别为９０％、７６．７％。两者结合显像阳性率为９６．７％。鳞状上皮细胞癌对９９ｍＴｃ（Ⅴ）－ＤＭＳＡ及９９ｍＴｃ－ＭＩＢＩ摄取程度比其它类型的肺癌高。     

^99mTc—MIBI心肌灌注显像潘生丁试验一天法在冠心病诊断中的应用

介绍了对１６１例冠心病患者采用＾９９ｍＴｃ－ＭＩＢＩ心肌显像潘生丁试验一天法方案进行检测的结果，其中２０例与冠状动脉造影进行了对比观察。患者先作＾９９ｍＴｃ－ＭＩＢＩ静态平面与断层心肌显像，接着进行潘生丁试验，再于静脉注射＾９９ｍＴｃ－ＭＩＢＩ后１ｈ作平面与断层心肌显像。采用本方法诊断冠心病的灵敏度为９１％。其检测ＬＡＤ的灵敏度为８８％；诊断ＲＣＡ及Ｌｃｘ的灵敏度分别为８１％与７７％、特异性分别为     

核素关节显像在类风湿关节炎病人中的应用

报道２０例次活动期类风湿关节炎病人的＾９９ｍＴｃ－人免疫球蛋白（ＨＩＧ）关节显像结果,其中１６例与＾９９ｍＴｃ－ＭＤＰ显像进行了对照。结果表明,所有病人＾９９ｍＴｃ－ＨＩＧ显像均为异常,表现为关节周围软组织即关节囊的放射性增高。它与临床的符合率明显高于＾９９ｍＴｃ－ＭＤＰ显像;每个病人临床总分与其显像总分之间呈显著性相关（Ｐ＜０．０１,ｒ＝０．９３）;临床累及且显像阳性的关节,其摄取放射性的多少与     

^99mTc—MIBI SPECT与^18F—FDG PET诊断胶质瘤复发及恶变对比分析

对２８例经过治疗的胶质瘤患者进行Ｇｄ－ＤＴＰＡＭＲＩ和＾１８Ｆ－ＦＤＧＰＥＴ显像，其中１４例同时进行＾９９ｍＴｃ－ＭＩＢＩＳＰＥＣＴ显像，并与治疗前解剖影像对比，ＰＥＴ结果发现１４例高代谢，１０例低代谢，４例瘤灶中心坏死，周边ＦＤＧ环状摄取，８例首次手术病理Ｉ－Ⅱ级星形细胞瘤患者中５例为高代谢，＾１８Ｆ－ＦＤＧＰＥＴ和＾９９ｍＴＣ－ＭＩＢＩＳＰＥＣＴ诊断胶质瘤复发及恶变的灵敏度依次为９３．３％，９     

^99mTc—MIBI评价缺血／再灌注心肌活力的实验研究

应用＾９９ｍＴＣ－ＭＩＢＩ对家兔缺血／再灌注心肌细胞及线粒体代谢和活力进行了评价，将家兔ＬＡＤ阻断２０ｍｉｎ，３ｈ再灌主，于灌注后２－５ｍｉｎ静脉注射＾９９ｍＴｃ－ＭＩＢＩ，结果缺血３ｈ组缺血心肌再灌注早期（１０ｍｉｎ）晚期（３ｈ）相对放射性活度，心肌ＡＴＰ含量均明显低于缺前２０ｍｉｎ组，非缺血心肌和缺血２０ｍｉｎ心肌＾９９ｍＴｃ－ＭＩＢＩ亚细胞分布与ＳＤＨ活性呈显著正相关（ｒ＝０．８８，Ｐ〈０．     

^99mTc标记抗心肌肌凝蛋白单克隆抗体在实验性心肌梗塞中的研究

为比较＾９９ｍＴｃ－ＡＭＬＡ的特异性，将两组心肌梗塞２４ｈ大鼠分别注射＾９９ｍＴｃ－ＡＭＬＡ（ｎ＝２４）和＾９９ｍＴｃ－Ｎ－ＩｇＧ（ｎ＝１８），为研究不同心肌梗塞时间对摄取抗体的影响，将另一组不同心肌梗塞时间（２ｈ到１４ｄ共８个亚组）的大鼠注射＾９９ｍＴｃ－ＡＭＬＡ，计算三组的ＩＤ％／ｇ和梗塞心肌摄取／正常心肌摄取比（ＩＭ／ＮＭ）用一只心肌梗塞的狗注射＾９９ｍＴｃ－ＡＭＬＡ后离体心肌显像，结果表明     

含服硝苯吡啶对99mTc-MIBI心肌显像的影响

为观察硝苯吡啶对＾９９ｍＴｃ－ＭＩＢＩ心肌断层显像的影响,把３５例冠心病患者分成硝苯吡啶组和硝酸甘油组,隔日行介入心肌断层显像,静注＾９９ｍＴｃ－ＭＩＢＩ后１ｈ和５ｈ时分别采集图象,分析结果显示硝苯吡啶组虽有４０．０％的心肌节段摄取较用药前改善,但１ｈ显像有３３个节段出现逆向性摄取减少,其中２９个节段５ｈ显像又恢复正常。硝酸甘油组有６９．５％心肌节段较用药前摄取改善,１ｈ显像未见有逆向性摄取减少,     

应用放射自显影术观察^99mTc—MIBI在大鼠甲甲状腺内的动态分布

报道了＾９９ｍＴｃ－ＭＩＢＩ在大鼠甲状腺内的动态分布。结果显示，甲状腺摄取＾９９ｍＴｃ－ＭＩＢＩ高峰在注药后３－６０ｍｉｎ，其前３ｍｉｎ主要与血供有关。１５－６０ｍｉｎ是腺体摄取的主要过程，为浓聚滞留时间，注药后６０ｍｉｎ内单位重量甲状腺组织摄取放射性大于同时间其它脏器和组织。放射自显影结果显示，在；甲状腺滤泡细胞周过部即上皮细胞及其周围银颗粒分布致密，而在滤泡腔内的胶质和滤泡间质内很少或基本未见     

半定量法201Tl双时相显像鉴别诊断甲状腺冷结节

为探讨甲状腺冷结节2 0 1Tl双时相显像的实用价值 ,取甲状腺单个冷结节患者 87例 ,静脉注射2 0 1Tl 12 1MBq后 15min显像及 12 0min延迟显像。按半定量法分别进行感兴趣区计数 ,计算结节组织与正常组织摄取比 (15min记为ER ,延迟记为DR)及滞留指数 [RI =(DR -ER) /ER×10 0 %]。结果表明 ,ER、DR和RI的恶性与非恶性组之间差异显著 (P <0 .0 5 )。囊性腺瘤者ER、DR和RI均明显低于恶性者 (P <0 .0 1) ;炎症者与恶性者比较差异不显著 (P >0 .0 5 )。半定量法的灵敏度、特异性和诊断正确率明显优于目视法 ,ER分别与DR、RI之间比较有显著性差异 (P <0 .0 5 )。显像结果提示 ,半定量法2 0 1Tl诊断显像可明显提高甲状腺单个冷结节的良、恶性质的诊断效率 ,具有临床应用价值。     

甲状腺滤泡型腺瘤~(201)TlCl显像观察

通过采用201TlCl对99mTcO4甲状腺显像的“冷结节”进行再显像，观察201TlCl显像对甲状腺滤泡型腺瘤临床应用的意义．在30例进行201TlCl显像患者中，仅选择其中19例经手术病理证实为甲状腺滤泡型腺瘤的患者作分析，其201TlCl显像结果为（－）6例，（＋）10例，（＋＋）3例，总阳性例数为13／19例。甲状腺滤泡型腺瘤虽为良性，但有浓聚201TlCl能力，此等病例应长期随访，观察甲状腺癌发生的情况。     

A comparative study of primary coronary stenting and intravenous thrombolysis for acute myocardial infarction using~(99m) Tc-MIBI SPECT imaging

1 INTRODUCTIONRe-perfusion therapy is one of the important progresses of acute myocardial infarction (AMI) therapy. It is established that early intravenous thrombolysis is effective and convenient for patency-related artery (IRA)[']. But obvious limitation existsfor thrombolysis application such as low IRA patency rate, recuxrent ischeAnc events,high re-infarction rate, hemorrhage complication and so many contraindications. Recentyearst primary coronary steming has been developed as …     

Preparation and preclinical studies of a hepatic receptor imaging agent

Galactosyl neoglycoalbumin(NGA) was synthesized by the covalent coupling of a bifunctional reagent ,2-imino-2-ethyloxymethy1-1-thiogalactose,to human serum albumin.The average number of galactose groups per albumin molecule(Gal/HSA) of NGA was 30.NGA was labeled directly with Na^99mTcO4.The radiochemical purity of ^99mTc-NGA was over 90%.Consequences of the preclinical studies show that ^99mTc-NGA is a good hepatic receptor imaging agent,uptaken by hepatic cells specifically,and excreted majorly from the biliary system and the gastrointestinal(GI) tract.     

Joint imaging of 99mTcO4- and 99mTc-MIBI for thyroid carcinoma recurrence and cervical metastases

In this paper, the joint imaging of 99mTcO4- and 99mTc-methoxy isobutyl isonitrile was compared with neck Color Doppler Ultrasonography (CDU) to identify its value in thyroid carcinoma, postoperative recurrence or cervical metastases. Thyroid carcinoma patients (150 operated and 21 re-operated with suspected postoperative recurrence or cervical metastases) were retrospectively analyzed. Taking the pathological result as the gold standard, the thyroid foci (437 cases), the thyroid foci of ≥1-cm diameter (215 cases) and the suspected postoperative recurrence or cervical metastases (87 cases) were compared by diagnostic results of the joint imaging and the neck CDU. The sensitivity, specificity and accuracy of the joint imaging were 64.18%, 80.00% and 67.82%, and 44.78%, 40.00% and 43.68%, respectively, for the cases with suspected postoperative recurrence or cervical metastases. For thyroid carcinoma of ≥1-cm diameter, the sensitivity of the joint imaging was 97.75%, and the neck CDU was 89.89%, but both specificity and accuracy was similar for thyroid carcinoma independence on their diameter. For thyroid carcinoma, the sensitivity of the joint imaging was 81.99%, and the neck CDU was 89.10%. The results show that the joint imaging is sensitive for large diameter thyroid carcinoma.     

~(99)Tc~m-MDP、~(99)Tc~m(V)-DMSA和~(99)Tc4~m-Citrate显像对骨组织良恶性疾病鉴别诊断的对比研究

为评价99Tcm(V)二巯基丁二酸钠(DMSA)显像和99Tcm枸缘酸(Citrate)显像在骨转移癌和骨及骨关节炎症诊断中的意义,对骨转移癌患者和骨及骨关节炎症患者各18例分别进行99Tcm亚甲基二膦酸(MDP)、99Tcm(V)DMSA和99TcmCitrate全身显像,并比较了它们的显像结果。18例经病理学、CT或MRI证实有骨转移癌的患者,99TcmMDP显像共检出64个病灶,99Tcm(V)DMSA显像显示在与99TcmMDP显像相同部位同检出49个病灶,而99TcmCitrate显像仅检出1个病灶。18例经细菌学、CT或MRI证实的骨及骨关节炎症患者,99TcmMDP显像共检出22个病灶,99Tcm(V)DMSA显像显示在与99Tcm MDP显像相同部位同检出17个病灶,99TcmCitrate显像检出16个病灶。本组病例99Tcm(V)DMSA显像诊断骨转移癌的灵敏度为76.56%,特异性为22.73%; 99TcmCitrate显像诊断骨转移癌的灵敏度仅为1.56%,特异性为27.27%。99Tcm(V)DMSA显像诊断骨及骨关节炎症的灵敏度为77.27%,特异性为23.44%;99TcmCitrate显像诊断骨及骨关节炎症的灵敏度为72.73%,特异性为98.44%。以上结果表明,99Tcm(V)DMSA显像在诊断骨转移癌和骨组织炎症时应该慎重,因为它不能区分骨组织的良恶性病变性质,其对骨组织的良恶性病变性质的鉴别诊断应排除外骨组织炎症、骨折等骨组织良性病变的干扰。而99TcmCitrate     

Diffusion characteristics of HTO and 99TcO4- in compacted Gaomiaozi (GMZ) bentonite

The characteristics of diffusion are essential to the transport of radionuclides through buffer/backfill materials, such as bentonite, which are commonly found in waste repositories. This study used through-diffusion techniques to investigate the diffusion behavior of HTO and ~(99)TcO_4~- on GMZ bentonite of various densities. Diffusion rates were calculated by measuring the diffusion coefficients(De, Da), plotting breakthrough curves and interpreting experiment data. The apparent and effective diffusion coefficients of HTO ranged from(1.68 ± 0.40) 9 × 10~(-11) to(2.80 ± 0.62) 9 × 10~(-11) m~2/s and from(4.61 ±1.28) 9 × 10~(-12) to (16.2 ± 2.50) 9 × 10~(-12) m~2/s, respectively.The apparent and effective diffusion coefficients of~(99)TcO_4~-ranged from(5.26 ± 0.16) 9 × 10~-12to(7.78 ± 0.43) 9× 10~-12m~2/s and from(1.49 ± 0.002) 9 × 10~(-12) to(4.16 ±0.07) 9 × 10~(-12) m~2/s, respectively. The distribution coefficients of HTO and~(99)TcO_4~-ranged from(0.70 ± 0.12) 9× 10~(-2) to(1.36 ± 0.53) 9 × 10~(-2) mL/g and from(1.12 ±0.06) 9 × 10~(-2) to(5.79 ± 2.22) 9 × 10~(-2) mL/g, respectively.The Deand Kdvalues were shown to decrease with an increase in the bulk dry density of compacted bentonite. Our results show that HTO and ~(99)Tc could be considered nonsorbent radionuclides. The data obtained in this studyprovide a valuable reference for the safety assessment of waste repositories.     

小肠原发恶性肿瘤18F-FDGPET/CT显像及诊断方法

44例小肠原发疾病患者(恶性25例,良性19例)18F-FDG PET/CT显像资料经组织学、诊断性治疗和/或临床随访证实;采用目测法、定量方法(测病变肠壁的厚度)及半定量方法[测平均标准摄取值(SUVmean)]分析PET/CT影像特点,以最大约登指数(YImax)时的SUVmean及肠壁厚度作为判断良恶性的阈值;以最后诊断结果为标准进行诊断学试验评价。结果显示:(1)小肠恶性肿瘤PET/CT表现为小肠局部肿块形成、局部肠壁增厚、肠管狭窄、肠梗阻及肠系膜淋巴结肿大等征象,而良性病变仅显示小肠肿块形成(χ2=10.40,p<0.01)、局部肠壁增厚(χ2=3.90,p<0.05),二征象有显著性差异。(2)小肠良、恶性病变肠壁厚度分别为(7.53±3.24)mm、(14.24±2.02)mm(t=2.66,p<0.01);YImax=0.589时,肠壁厚度为9.5 mm,诊断灵敏度、特异性和准确度分别为80.00%、78.95%和79.55%。(3)小肠良、恶性病变的SUVmean分别为3.55±1.84、6.98±3.62(t=3.77,p<0.01);YImax=0.379时,SUVmean=3.65,诊断灵敏度、特异性和准确度分别为80.00%、58.85%和70.45%。(4)以小肠肿块形成作为恶性的判断标准,诊断的灵敏度、特异性和准确度分别为84.00%、78.95%和81.82%,YImax=0.630。(5)以小肠局部肿块形成及病灶SUVmean≥3.65、局部肠壁增厚及厚度≥9.50 mm为主要依据,诊断灵敏度、特异性和准确度分别为96.00%、89.47%和93.18%,YImax=0.855。表明18F-FDG PET/CT显像提示小肠局部肿块形成及病灶SUVmean≥3.65、局部肠壁增厚及厚度≥9.50 mm的定性定量征象对准确诊断小肠原发恶性肿瘤具有重要的临床价值。